Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08 | Direct | 6,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 310,420 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 96,250 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2025-01-06 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 88,351 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-22 · Disposition to issuer · Disposed 39,375 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2026-07-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2027-01-18 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-22 · Disposition to issuer · Disposed 47,916 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2027-04-26 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-22 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.21 · Expires 2027-10-26 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-22 · Disposition to issuer · Disposed 621,101 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.69 · Expires 2028-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-22 · Disposition to issuer · Disposed 146,875 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-22 · Disposition to issuer · Disposed 314,120 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2030-05-14 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-22 · Disposition to issuer · Disposed 536,032 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-22 · Disposition to issuer · Disposed 284,712 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-22 · Disposition to issuer · Disposed 649,999 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-22 · Disposition to issuer · Disposed 800,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2024-03-22 · Disposition to issuer · Disposed 357,500 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001588861-26-000002 · form4-06112026_040605.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 21:15 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001415889-25-011108 · form4-04212025_050404.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 22:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 8,047 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001415889-25-010979 · form4-04172025_060407.xml · derivative · entry 2 Shah Sujal · CIK 0001588861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,047 Underlying: Common Stock · 8,047 shares Expires 2031-12-15 F3 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F5 · price: Received in exchange for a stock option to acquire 60,000 shares of common stock of Legacy Tvardi with the exercise price of $0.63 per share pursuant to the Merger Agreement. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 22:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 10,394 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001415889-25-010979 · form4-04172025_060407.xml · derivative · entry 1 Shah Sujal · CIK 0001588861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,394 Underlying: Common Stock · 10,394 shares Expires 2031-01-29 F2 · price: Received in exchange for a stock option to acquire 77,500 shares of common stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") with the exercise price of $0.09 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement"). F3 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 357,500 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 15 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 357,500 shares Expires 2034-01-23 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 800,000 | Not disclosed Strike: $7.80 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 14 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires 2033-01-24 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 649,999 | Not disclosed Strike: $2.94 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 13 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 649,999 shares Expires 2032-01-24 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 284,712 | Not disclosed Strike: $5.78 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 12 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 284,712 shares Expires 2031-01-25 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 536,032 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 11 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 536,032 shares Expires 2030-05-14 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 314,120 | Not disclosed Strike: $8.43 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 10 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 314,120 shares Expires 2029-01-28 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 146,875 | Not disclosed Strike: $11.69 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 9 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,875 shares Expires 2028-01-23 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 621,101 | Not disclosed Strike: $9.21 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 8 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 621,101 shares Expires 2027-10-26 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $3.48 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 7 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2027-04-26 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 47,916 | Not disclosed Strike: $1.72 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 6 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,916 shares Expires 2027-01-18 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-07-24 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 39,375 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,375 shares Expires 2026-01-25 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 88,351 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · derivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,351 shares Expires 2025-01-06 F3 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerCommon Stock | 96,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 16:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerCommon Stock | 310,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035447 · ownership.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 18 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,799 Underlying: Common Stock · 1 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,288 | $0.00 Strike: $5.78 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 17 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,845 Underlying: Common Stock · 2,288 shares Expires 2031-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2021. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 22,076 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 16 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,076 shares Expires 2030-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 31, 2020. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,372 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 15 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,372 shares Expires 2029-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 14 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2028-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,899 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 13 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,899 shares Expires 2027-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from October 27, 2017. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 52,084 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 12 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,084 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,625 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 11 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,625 shares Expires 2026-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,649 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · derivative · entry 10 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,649 shares Expires 2025-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on the first anniversary of the grant date, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 1 | $2.94 | $2.94 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 9 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 2,288 | $5.78 | $13,224.64 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 8 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 22,076 | $4.05 | $89,407.80 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 7 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 14,372 | $8.43 | $121,155.96 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 6 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 3,125 | $11.69 | $36,531.25 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 18,899 | $9.21 | $174,059.79 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 52,084 | $1.72 | $89,584.48 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 14,625 | $1.06 | $15,502.50 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 11,649 | $10.00 | $116,490.00 |
DisclosureSEC source: 0001062993-24-006513 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:27 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 357,500 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001062993-24-001426 · form4.xml · derivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,500 Underlying: Common Stock · 357,500 shares Expires 2034-01-23 F2 · derivative.exercise_date: The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:27 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantCommon Stock | 96,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001426 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,551 F1 · shares: The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,856 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · derivative · entry 7 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,856 shares Expires 2024-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Appreciation Right · Derivative | 12,973 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · derivative · entry 6 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,973 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 31,036 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · derivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,036 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 890 | $20.81 | $18,520.90 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · nonDerivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 890 | $5.00 | $4,450.00 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · nonDerivative · entry 3 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 63,975 | $19.99 | $1,278,649.13 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · nonDerivative · entry 2 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.56, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 19:03 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 63,975 | $5.00 | $319,875.00 |
DisclosureSEC source: 0001062993-23-022368 · form4.xml · nonDerivative · entry 1 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,855 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · derivative · entry 7 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,856 Underlying: Common Stock · 20,855 shares Expires 2024-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionStock Appreciation Right · Derivative | 12,972 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · derivative · entry 6 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,973 Underlying: Common Stock · 12,972 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 31,036 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · derivative · entry 5 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,036 Underlying: Common Stock · 31,036 shares Expires 2023-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 18:00 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 20,855 | $15.89 | $331,350.50 |
DisclosureSEC source: 0001062993-23-020835 · form4.xml · nonDerivative · entry 4 Shah Sujal · CIK 0001588861 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $16.28, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.